Preliminary data suggests that VH-499 does not significantly inhibit or induce CYP3A4, which is favorable for safety. Future Outlook
What is the associated with it?
Unlike traditional antiretrovirals that target enzymes like reverse transcriptase or protease, VH-499 disrupts the capsid’s integrity. Its mechanism is similar to Lenacapavir but acts at both early and late stages of the viral life cycle: GVH-499
Because it works at two different stages of the viral cycle, the barrier to resistance is expected to be high, meaning the virus cannot easily evolve to bypass it. Preliminary data suggests that VH-499 does not significantly